Viridian Therapeutics (VRDN) CMO receives new option and RSU grants

Q: How many stock options were granted to the Viridian Therapeutics (VRDN) Chief Medical Officer?

The Chief Medical Officer received stock options covering 95,800 shares of Viridian Therapeutics common stock. The options were granted at an exercise price of $0.00 per share and vest in 48 equal monthly installments, subject to her continued service with the company.

Q: How many restricted stock units did the Viridian Therapeutics (VRDN) CMO receive?

The Chief Medical Officer received 19,150 restricted stock units (RSUs) . Each RSU represents a contingent right to receive one share of Viridian Therapeutics common stock, delivering actual shares only as the RSUs vest over the specified time schedule.

Q: What is the vesting schedule for the Viridian Therapeutics (VRDN) CMO restricted stock units?

The RSUs vest over four years , with 25% of the units vesting on each yearly anniversary of the March 2, 2026 grant date. Vesting requires the Chief Medical Officer to remain in service with Viridian Therapeutics through each annual vesting date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Viridian Therapeutics Chief Medical Officer Radhika Tripuraneni reported equity awards consisting of stock options and restricted stock units. She acquired stock options for 95,800 shares at an exercise price of $0.00 per share, with the grant dated March 2, 2026. These options vest in 48 equal monthly installments, conditioned on continued service. She also received 19,150 restricted stock units, each representing one share of common stock. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the March 2, 2026 grant date, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tripuraneni Radhika

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	95,800	$0.00	--
Grant/Award	Restricted Stock Units	19,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 95,800 shares (Direct); Restricted Stock Units — 19,150 shares (Direct)

Footnotes (1)

The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/04/2026 - 06:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tripuraneni Radhika

(Last)

(First)

(Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$30.25	03/02/2026		A		95,800		⁽¹⁾	03/02/2036	Common Stock	95,800	$0	95,800	D
Restricted Stock Units	⁽²⁾	03/02/2026		A		19,150		⁽³⁾	⁽³⁾	Common Stock	19,150	$0	19,150	D

Explanation of Responses:

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

	Jennifer Tousignant, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Viridian Therapeutics (VRDN) report for its Chief Medical Officer?

Viridian Therapeutics reported that Chief Medical Officer Radhika Tripuraneni received grants of stock options and restricted stock units on March 2, 2026. These equity awards are compensation-based, with future vesting tied to her continued service with the company over several years.

How many stock options were granted to the Viridian Therapeutics (VRDN) Chief Medical Officer?

The Chief Medical Officer received stock options covering 95,800 shares of Viridian Therapeutics common stock. The options were granted at an exercise price of $0.00 per share and vest in 48 equal monthly installments, subject to her continued service with the company.

What are the vesting terms for the Viridian Therapeutics (VRDN) CMO stock options?

The stock options granted to the Chief Medical Officer vest in 48 equal monthly installments after the March 2, 2026 grant date. Vesting is conditioned on her continued service to Viridian Therapeutics through each monthly vesting date, gradually increasing her exercisable option holdings.

How many restricted stock units did the Viridian Therapeutics (VRDN) CMO receive?

The Chief Medical Officer received 19,150 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Viridian Therapeutics common stock, delivering actual shares only as the RSUs vest over the specified time schedule.

What is the vesting schedule for the Viridian Therapeutics (VRDN) CMO restricted stock units?

The RSUs vest over four years, with 25% of the units vesting on each yearly anniversary of the March 2, 2026 grant date. Vesting requires the Chief Medical Officer to remain in service with Viridian Therapeutics through each annual vesting date.

Do the Viridian Therapeutics (VRDN) RSUs equal common stock upon vesting?

Each restricted stock unit represents a contingent right to receive one share of common stock of Viridian Therapeutics. When RSUs vest under the schedule, the holder becomes entitled to receive a corresponding number of common shares from the company.